

# Neurofibromatosis Type 1 (NF1) Variant Analysis Report

ClinVar Data Analysis - Chromosome 17

Gene: NF1 (Gene ID: 4763)

Date: October 1, 2025

**Summary:** Analysis of 7 NF1 variants from ClinVar database (GRCh37/hg19 reference). Three pathogenic variants identified with strong clinical evidence (splice site, nonsense, and frameshift mutations). One variant shows conflicting interpretations requiring additional clinical context.

## 1. Pathogenic Variants (Disease-Causing)

**Variant 1: chr17:29654516 G>A**

**dbSNP ID:** rs876660141

**Variant Type:** Splice acceptor variant

**Clinical Significance:** Pathogenic

**Review Status:** Criteria provided, multiple submitters, no conflicts

**Molecular Consequence:** SO:0001574 (splice acceptor variant)

**Clinical Impact:** Disrupts normal RNA splicing, likely resulting in aberrant transcript and loss of protein function

**Origin:** Germline (inherited) and de novo

**Variant 2: chr17:29657379 T>A****dbSNP ID:** rs2069450324**Variant Type:** Nonsense (stop-gain)**Clinical Significance:** Pathogenic**Review Status:** Criteria provided, single submitter**Molecular Consequence:** SO:0001587 (nonsense)**Clinical Impact:** Introduces premature stop codon leading to truncated, non-functional protein**Origin:** Germline**Variant 3: chr17:29552220 AC>A (1bp deletion)****dbSNP ID:** rs1597710675**Variant Type:** Frameshift deletion**HGVS:** NC\_000017.10:g.29552221del**Clinical Significance:** Pathogenic**Review Status:** Criteria provided, multiple submitters, no conflicts**Molecular Consequence:** SO:0001589 (frameshift variant)**Clinical Impact:** Frameshift mutation disrupting reading frame and causing protein dysfunction**Origin:** Germline

## 2. Variant with Conflicting Evidence

---

**Variant 4: chr17:29592354 G>A****dbSNP ID:** rs876659197**Variant Type:** Missense variant**Clinical Significance:** **Conflicting classifications**

- Likely pathogenic: 1 submitter
- Uncertain significance: 6 submitters

**Review Status:** Criteria provided, conflicting classifications**Associated Phenotypes:** Neurofibromatosis type 1, Juvenile myelomonocytic leukemia, Cardiovascular phenotype**Note:** Requires family segregation studies and additional functional evidence for definitive classification**Origin:** Germline

### 3. Variant of Uncertain Significance (VUS)

---

**Variant 5: chr17:29654553 C>G****dbSNP ID:** rs876657714**Variant Type:** Missense variant**Clinical Significance:** Uncertain significance**Review Status:** Criteria provided, single submitter**Molecular Consequence:** SO:0001583 (missense variant)**Note:** Insufficient evidence to determine pathogenicity; not recommended for clinical decision-making without additional data**Origin:** Germline

### 4. Likely Benign / Benign Variants

---

**Variant 6: chr17:29557957 G>T**

**dbSNP ID:** rs764474296

**Variant Type:** Intronic variant

**Clinical Significance:** Likely benign

**Review Status:** Criteria provided, single submitter

**Allele Frequency (ExAC):** 0.00001 (1 in 100,000)

**Note:** Located in intron; unlikely to affect protein function

**Variant 7: chr17:29684304 T>C**

**dbSNP ID:** rs767860040

**Variant Type:** Synonymous variant

**Clinical Significance:** Likely benign

**Review Status:** Criteria provided, multiple submitters, no conflicts

**Allele Frequency (ExAC):** 0.00001 (1 in 100,000)

**Molecular Consequence:** SO:0001819 (synonymous variant)

**Note:** Silent mutation; does not change amino acid sequence

5. Summary Table

Position	Change	Type	Significance	dbSNP
29654516	G>A	Splice acceptor	Pathogenic	rs876660141
29657379	T>A	Nonsense	Pathogenic	rs2069450324
29552220	AC>A	Frameshift	Pathogenic	rs1597710675
29592354	G>A	Missense	Conflicting	rs876659197
29654553	C>G	Missense	Uncertain	rs876657714
29557957	G>T	Intronic	Likely benign	rs764474296
29684304	T>C	Synonymous	Likely benign	rs767860040

## 6. Key Clinical Insights

---

- **Loss-of-function mutations predominate:** The pathogenic variants include splice site, nonsense, and frameshift mutations, all resulting in loss of NF1 protein (neurofibromin) function
- **Haploinsufficiency mechanism:** NF1 acts as a tumor suppressor gene; one mutated copy is sufficient to increase disease risk through reduced neurofibromin levels
- **Mutation spectrum:** The variety of mutation types reflects the large size of the NF1 gene and multiple mechanisms of pathogenicity
- **Conflicting evidence:** The missense variant at position 29592354 requires additional clinical context, segregation data, and functional studies for definitive interpretation
- **Phenotypic variability:** Some variants are associated with additional features beyond classic NF1, including cardiovascular abnormalities and increased risk of juvenile myelomonocytic leukemia
- **Clinical testing considerations:** Pathogenic variants should be confirmed with orthogonal methods; VUS results require genetic counseling regarding limitations

## 7. Recommendations

---

- Pathogenic variants (positions 29654516, 29657379, 29552220) are reportable findings consistent with NF1 diagnosis
- The conflicting variant (29592354) should be classified as VUS unless additional evidence becomes available
- Variants of uncertain significance should not be used alone for clinical decision-making
- Genetic counseling is recommended for all patients with NF1-related findings
- Regular monitoring according to NF1 clinical guidelines is appropriate for confirmed pathogenic variant carriers

---

**Data Source:** ClinVar VCF file (GRCh37/hg19 reference assembly)

**Reference Genome:** GRCh37 (hg19)

**Analysis Date:** October 1, 2025

**Note:** This report is for research and informational purposes. Clinical interpretation should be performed by qualified healthcare professionals with appropriate genetic counseling.